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Abstract
Background: Combination vaccines reduce the total number of injections required for each
component administered separately and generally provide the same level of disease protection.
Yet, physical, chemical, and biological interactions between vaccine components are often
detrimental to vaccine safety or efficacy.
Methods:  As a possible alternative to combination vaccines, we used specially designed
microneedles to inject rhesus macaques with four separate recombinant protein vaccines for
anthrax, botulism, plague and staphylococcal toxic shock next to each other just below the surface
of the skin, thus avoiding potentially incompatible vaccine mixtures.
Results: The intradermally-administered vaccines retained potent antibody responses and were
well- tolerated by rhesus macaques. Based on tracking of the adjuvant, the vaccines were
transported from the dermis to draining lymph nodes by antigen-presenting cells. Vaccinated
primates were completely protected from an otherwise lethal aerosol challenge by Bacillus anthracis
spores, botulinum neurotoxin A, or staphylococcal enterotoxin B.
Conclusion: Our results demonstrated that the physical separation of vaccines both in the syringe
and at the site of administration did not adversely affect the biological activity of each component.
The vaccination method we describe may be scalable to include a greater number of antigens, while 
avoiding the physical and chemical incompatibilities encountered by combining multiple vaccines 
together in one product.
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Background
Vaccination compliance will predictably become a signif-
icant concern as current schedules approach the limit of
public acceptance [1] and new vaccines become available.
The development of combination vaccines is a common
practice that addresses the concern of repeated visits to the
clinic by reducing the total number of injections required
compared with administration schedules for the monova-
lent vaccines. Yet, physical, chemical, and biological inter-
actions between the components of combination vaccines
must be considered to avoid detrimental effects on safety
or efficacy. For example, when the Haemophilus influenzae
type b (Hib) vaccine was combined with diphtheria, teta-
nus, and acellular pertussis vaccine, a decrease in antibody
titer for the Hib vaccine was observed [2]. Thus, there is a
need to develop new approaches for delivery of multiple
vaccines.
We evaluated delivery of multiple vaccines intradermally
(i.d.) to physically isolate each component, thus directly
preventing formulation incompatibilities prior to admin-
istration. The physiological fate of vaccines administered
i.d. is not known. However, vaccination by microneedles
[3] permits verification of the physical deposition into the
skin while intramuscular (i.m.) injection sites are inacces-
sible for direct observation. Further, i.d. vaccination using
microneedles is less painful [3] than i.m. injection by con-
ventional needles and provides an increased immune
response with a lower amount of vaccine than that
required by intramuscular (i.m.) methods [4,5]. The
greater efficacy resulting from i.d. vaccination may permit
the administration of an increased number of vaccines
compared to i.m. because a smaller volume is required for
delivery.
The pre-clinical phase of vaccine development tradition-
ally focuses on a single disease of concern, often targeting
a protein that is critical to pathology. Because emerging
infectious diseases and agents of concern to biodefense
contribute substantially to the burden of new vaccines, we
specifically examined vaccines for anthrax, botulism,
toxic-shock syndrome, and plague. The following is a brief
description of the diseases and vaccines that were devel-
oped for prevention.
Bacillus anthracis, the etiological agent of anthrax, pro-
duces binary toxins [6-9] comprised of protective antigen
(PA) combined with lethal factor (LF) or edema factor
(EF). The vaccine employed in our study was a recom-
binant form of PA (rPA) that was previously shown to
protect rhesus macaques from aerosol challenge with B.
anthracis  spores [10,11]. Antibodies that neutralize PA
block the transport of LF and EF to the cytosol, thereby
blocking cell death induced by the toxins. Botulinum neu-
rotoxin type A (BoNT/A) causes botulism by blocking the
release of acetylcholine at the neuromuscular junction
[12]. A recombinant C fragment vaccine of botulinum
neurotoxin type A [BoNT/A(Hc)] was developed that does
not possess the toxic properties of the wild-type protein
[13]. In previous studies, the BoNT/A(Hc) was shown to
be effective at protecting vaccinated mice against chal-
lenge with the wild-type toxin [13]. Antibodies that pre-
vent botulism are presumed to inhibit binding of the
toxin to neurons and thereby impede entry of the toxin
into the cell. Staphylococcal enterotoxin B (SEB) is a viru-
lence factor expressed by most isolates of the common
human pathogen Staphylococcus aureus [14,15]. Secreted
SEB binds and cross-links class II molecules of the major
histocompatibility complex expressed on antigen-present-
ing cells to the antigen receptors on T cells, leading to
potent activation of the immune system. Life-threatening
toxic shock syndrome may result from the rapid release of
high levels of IFN-γ, IL-6, TNF-α and other cytokines in
response to SEB. The recombinant SEB vaccine (STEBVax)
contains three site-specific mutations that collectively
alter key protein surfaces, leading to loss of receptor bind-
ing and superantigen activity [16]. This vaccine was
shown in previous studies to protect rhesus macaques
from aerosol challenge with SEB [17] and protection from
toxic shock in vaccinated monkeys correlated with SEB
neutralization by antibodies [17]. We also examined an
experimental plague vaccine (F1-V) consisting of a recom-
binant fusion protein of the bacterial antigens CaF1 and
LcrV, previously shown to protect mice against plague
[18,19]. The bubonic form of plague results from Yersinia
pestis injected into the skin by the bite of infected fleas and
is characterized by acute painful swelling of regional
lymph nodes. Progression to septicemic or secondary
pneumonic plague may also ensue. Primary pneumonic
plague may also occur by transfer of bacteria through aer-
osols produced by coughing. Although mouse data are
available [18,19], there are no reports that address protec-
tion of non-human primates that were vaccinated with
F1-V and challenge with Y. pestis. However, we included
F1-V in our study to increase the complexity of the vaccine
combination and because this high-profile product is ulti-
mately intended for human use.
All of the vaccines we investigated were developed inde-
pendently, using buffers and additives that were poten-
tially incompatible if all antigens were directly mixed due
to differences in pH, buffers, and stability profiles. For
example, STEBVax was maintained in a glycine buffer of
pH 8, while a phosphate buffer of pH 7 was used for rPA.
Yet, an advantage associated with the vaccines for anthrax,
botulism and staphylococcal toxic shock is that all were
previously examined in studies using rhesus macaques
[[10,11,17], and unpublished observations], allowing us
to measure survival from an otherwise lethal sepsis in the
same animal disease model. Although co-formulationJournal of Immune Based Therapies and Vaccines 2008, 6:5 http://www.jibtherapies.com/content/6/1/5
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may ultimately be achievable for many vaccines, physical
separation obviates the need for additional costly studies
to re-examine safety, stability, and efficacy. We hypothe-
sized that the physical separation of vaccines both in the
syringe and at the site of administration will not adversely
affect the biological activity of each component.
Methods
Vaccinations
The recombinant botulinum neurotoxin serotype A bind-
ing domain BoNT/A(Hc), SEB vaccine (STEBVax) and the
fusion protein of F1 and V antigens (rF1-V) were prepared
as previously described [10,13,16,19]. The recombinant
protective antigen (rPA) was obtained from List Laborato-
ries (Wako, TX). Each vaccine was combined with AH
adjuvant (Superfos Biosector, Kvistgård, Denmark),
before administration using previously optimized ratios
(unpublished observations) that in all cases resulted in
delivery of < 1 mg of elemental aluminum per animal.
Rhesus monkeys were obtained from Primate Products,
Inc. (Woodside, CA) and quarantined for 30 d before
study initiation. Just before vaccination, anesthetized
(ketamine/acepromazine) monkeys were shaved on the
deltoid/upper arm region or thigh using electric clippers,
and the vaccines were administered i.d. on days 0, 28, and
56. On day 0 the vaccines were administered on the left
arm, on day 28 the vaccines were administered on the
right arm, and on day 56 the vaccines were administered
on the left thigh. Vaccinated animals received 5 μg of the
BoNT/A(Hc) vaccine, 150 μg of rF1-V, 50 μg of rPA, and
40 μg of STEBVax. Control animals received injection of
AH adjuvant with no antigen. Two 100-μl i.d. injections
of each vaccine were administered 2 cm apart with a stain-
less steel microneedle (1-mm exposed length, 76-μm
inner diameter, 178-μm outer diameter) attached to a 1-
ml syringe, as previously described [20].
Serology
Complete blood counts with white blood cell differential
counts as well as serum concentrations of IgM and IgG
were determined from blood collected on days 14, 42,
and 70. Before each blood draw, animals were anesthe-
tized by injection with ketamine/acepromazine. Antigen-
specific serum antibody levels were determined by ELISA.
Plastic plates (96 well) were coated (1 h, 37°C) with 100
μl/well of 2 μg/ml of BoNT/A(Hc), rF1-V, rPA, or STEBVax
diluted in PBS (pH 7.4) for the sample unknowns, and
purified monkey IgM or IgG was serially diluted threefold
for the standard curve. The plates were washed three times
with PBS/0.1% Tween and blocked (1 h, 37°C) with 0.2%
casein/PBS (100 μl/well), washed as above, and then were
incubated (1 h, 37°C) with 100 μl of diluted serum sam-
ples. Plates were then washed and incubated (1 h, 37°C)
with 100 μl/well of goat anti-monkey IgG or goat anti-
monkey IgM (1:10,000 dilutions) conjugated to horserad-
ish peroxidase, washed, and developed (30 min, 22°C)
with 100 μl of TMB peroxidase substrate (KPL, Gaithers-
burg, MD). Absorbance was measured at 650 nM and con-
centrations were determined by comparison to the
absorbance of the standard curve.
Neutralizing antibody assays
For the anthrax toxin neutralization assay, 100 ng/ml LF
and 200 ng/ml of PA, both in high-glucose DMEM with
7.5% fetal bovine serum (FBS), were mixed 1:1 with dilu-
tions of sera and incubated for 1 h (37°C) before being
added to J774 cells growing on a 96-well plate (63,000
cells/well in high-glucose DMEM, 7.5% FBS). The cells
were incubated at 37°C for 4 h and cell viability was deter-
mined by ATP content (Vialight HS, Cambrex, Rockland,
ME). The endpoint titer was determined as the serum dilu-
tion that gave a response three times greater than back-
ground. For the SEB neutralization assay, human
peripheral blood mononuclear cells were isolated by den-
sity gradient centrifugation and added to a 96-well plate
(100,000 cells/well in RPMI, 5% fetal calf serum). After
plating, cells were allowed to rest for 2 h at 37°C. Dilu-
tions of the test and control sera were prepared and SEB
(200 ng/ml) was added to each dilution. Serum dilutions
were then incubated for 1 h. at 37°C. The treatments (50
μl/well) were added to the cells and the plates were incu-
bated at 37°C for 60 h. Finally, 1 μCi of [3H] thymidine
(Sigma, St. Louis, MO) was added to each well, the plates
were incubated for 9 h at 37°C, and incorporated radioac-
tivity was measured by liquid scintillation. The antibody
titer was determined as the highest serum dilution that
significantly inhibited (Student's t-test) SEB-induced pro-
liferation of the monocytes compared to the negative con-
trol. For the BoNT/A neutralization assay, dilutions of
serum from animals in the BoNT/A challenge groups were
mixed with 10 LD50 of toxin and incubated for 1 h at room
temperature. Each dilution was injected intraperitoneally
(IP) into four CD-1 mice. The mice were observed for 4
days and the number of deaths in each group was
recorded. The neutralizing antibody titer was determined
as the reciprocal of the serum dilution that protected 50%
of the mice from intoxication with BoNT/A.
Aerosol challenge
Animals were split into four separate challenge groups,
each containing two controls and six vaccinated monkeys.
Each group was challenged with one agent: BoNT/A, Ames
strain spores of B. anthracis, or SEB, all obtained from
USAMRIID. Before challenge, monkeys were anesthetized
with ketamine/acepromazine and their breathing rate was
determined by plethysmography. For groups challenged
with botulinum neurotoxin A (50 LD50), B. anthracis (200
LD50), or SEB (25 LD50), each animal was exposed to the
agent for 10 min in a head-only exposure chamber. Ani-
mals were observed up to two months after challenge. OnJournal of Immune Based Therapies and Vaccines 2008, 6:5 http://www.jibtherapies.com/content/6/1/5
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days 2, 4, and 6 postchallenge, blood was drawn and com-
plete blood counts with white blood cell differential
counts were performed on all samples and bacteremia was
determined for samples from animals challenged with
bacterial agents. Necropsies were performed on animals
that did not survive to verify death was a result of exposure
to the challenge agent.
Pathology and necropsy
A necropsy was performed on all animals, either as soon
as death occurred from infection or intoxication or after
humane euthanasia of terminally ill or moribund animals
by established protocols. Samples of spleen, lymph nodes
(mandibular, axillary, tracheobronchial, mesenteric),
lung, trachea, mediastinum, and haired skin from the vac-
cine sites from each monkey were collected for histopa-
thology. Additionally, brain tissue was collected from
animals that succumbed due to infection with B. anthracis.
All tissues were immersion-fixed in 10% neutral buffered
formalin.
Histology and immunohistochemistry
Formalin-fixed tissues for histology were trimmed, proc-
essed, and embedded in paraffin according to established
protocols [21]. Histology sections were cut at 5–6 μm,
mounted on glass slides, and stained with hematoxylin &
eosin (H&E). Immunohistochemical staining was per-
formed using the Envision+ method (DAKO, Carpinteria,
CA). Briefly, sections were deparaffinized in Xyless, rehy-
drated in graded ethanol, and endogenous peroxidase
activity was quenched in a 0.3% hydrogen peroxide/
methanol solution for 30 min at room temperature. Slides
were washed in distilled water, placed in a Tris-EDTA
Buffer (10 mM Tris Base, 1 mM EDTA Solution, 0.05%
Tween 20, pH 9.0) and heated in a vegetable steamer for
30 min. Sections were incubated in the primary antibody,
rabbit anti-major histocompatibility complex class II pol-
yclonal antibody (RGU, unpublished), diluted 1:500 for 1
h at room temperature. After the primary antibody incu-
bation, sections were washed in PBS and incubated for 30
min with Envision + System HRP (horseradish peroxi-
dase-labeled polymer conjugated to goat anti-rabbit
immunoglobulins) at room temperature. Peroxidase
activity was developed with 3,3'-diaminobenzidine
(DAB), counterstained with hematoxylin, dehydrated,
cleared in Xyless, and coverslips were applied with Per-
mount.
Adjuvant visualization in tissues
Adjuvant was localized in tissue samples by detection of
aluminum. Five micrometer sections were prepared from
formalin fixed, paraffin-embedded tissue blocks, depar-
affinized in Xyless, and rehydrated in graded alcohols.
Slides were rinsed in distilled water then pretreated in a
1% aqueous solution of hydrochloric acid for 10 min.
After rinsing the slides in distilled water for 5 min, we
stained them in a 0.2% alcoholic Morin solution (Sigma,
Atlanta, GA) for 10 min. After staining with Morin, the
sections were incubated for 2 h at 37°C with a 1:20 dilu-
tion of Texas Red phalloidin and approximately 1 μg/ml
of Hoechst-33258 (Molecular Probes, Eugene Oregon) in
PBS. Sections were rinsed twice in PBS and once in water
before coverslips were applied with Vecta Shield mount-
ing medium (Vector Labs, Burlingame, CA).
Confocal microscopy
Images were collected with a BioRad 2000 MP confocal
system attached to a Nikon TE300 inverted microscope
fitted with a 60× (1.20 N.A.) water-immersion objective
lens. Morin fluorescence was detected with 488 nm laser
excitation and a HQ515/30 emission filter. Texas Red
phalloidin was imaged with 568 nm laser excitation and
an E600LP emission filter. Hoechst dye was visualized
with 800 nm 2-photon excitation and a HQ390/70 emis-
sion filter. Subsequent contrast enhancement of the
resulting images was performed using Adobe PhotoShop
software.
Statistical analysis
Analysis of variance was used to analyze serology data
obtained at various time points after vaccine administra-
tion to determine if there were any statistical differences
within or between the vaccinated and control groups. The
data conformed with the assumptions of the test if plots
of the residuals revealed no structure. Comparisons of
antibody production and lymphocyte proliferation
between vaccinated and control animals were performed
using Student's t-test. The data conformed to the assump-
tions of the t-test if the normal probability plot was a
straight line. Historical controls were used to increase the
statistical power of the experiment. Uniform lethality was
observed in more than 15 untreated control Rhesus
exposed to the same strain and route of each agent used in
the experiment. Efficacy was evaluated using Fishers exact
test comparing the treated group to the control group for
each agent consisting of 2 experimental controls and 15
historical controls.
Results
Intradermal administration of physically separated 
vaccines
A simple mixture of the BoNT/A(Hc), F1-V, rPA and STE-
BVax as currently formulated resulted in formation of a
precipitation and a significant change in pH of the solu-
tion (data not shown). Because of these apparent chemi-
cal incompatibilities we were not able to examine animals
vaccinated with simple mixtures of the vaccines. The vac-
cines BoNT/A(Hc), F1-V, rPA and STEBVax were individu-
ally administered three times, 28 d apart, by injection into
the shaved dermis of the upper arm or thigh of rhesusJournal of Immune Based Therapies and Vaccines 2008, 6:5 http://www.jibtherapies.com/content/6/1/5
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macaques using stainless steel microneedles that were the
approximate diameter of a human hair, as previously
reported [18-21]. The subject animals received doses of
each vaccine that were independently optimized
[11,13,17,19] and adsorbed to aluminum hydroxide
adjuvant (AH). Control animals received i.d. injections of
AH alone. The pattern of vaccinations consisted of an
array of 100-μl injections separated by 2 cm, keeping each
vaccine isolated from adjacent administrations (Fig. 1).
No visible indications of discomfort were noted in any
animal after vaccination. Slight erythema was evident at
sites of second or third vaccinations, suggesting a robust
recall immune response. Small raised blebs appeared on
the skin at each injection site (Fig. 1A) immediately after
vaccine administration, and the sites were only slightly
perceptible on the surface of the skin up to 2 months later
(Fig 1B). Histology performed on tissue samples obtained
from the delivery site showed AH localized within the der-
mis after administration and a granulomatous response to
vaccination in both the controls and vaccinates (Fig. 1C).
Numerous phagocytes and multinucleated giant cells
were present in the dermis and panniculus at the injection
site and the phagocytes contained abundant intracyto-
plasmic blue-gray granular material (Fig. 1C). Histochem-
ical staining of the tissue with Morin, a dye that is
fluorescent green upon chelation of aluminum, demon-
strated positive staining of the intracytoplasmic granular
material, which verified the presence of aluminum from
the vaccine adjuvant (Fig. 1C inset). Immunohistochemi-
cal staining of the skin revealed that the phagocytes exhib-
ited expression of MHC-II molecules (Fig. 1D).
Examination of tissue from the axillary lymph nodes
revealed phagocytes that contained a similar intracyto-
plasmic granular material as the skin sections (Fig. 1E). As
before, staining the tissue with Morin revealed positive,
fluorescent intracytoplasmic granules, verifying the mate-
rial was aluminum from the vaccine adjuvant (Fig. 1E
inset). These results suggest that the vaccines were trans-
ported from the dermal injection site to the draining
lymph nodes.
Several diagnostic parameters were monitored during the
study to evaluate the safety of simultaneous administra-
tion of multiple vaccines. Vaccine administration did not
significantly affect the white blood cell counts of either
the controls or vaccinated animals (Fig. 1E). No abnor-
malities were noted in red blood cell count, platelets,
hemoglobin, hematocrit, mean corpuscular volume,
mean corpuscular hemoglobin, mean corpuscular hemo-
globin concentration, red cell distribution width, or mean
platelet volume, and no significant changes were noted in
blood chemistries (data not shown). Collectively, these
results suggested that i.d. administration of multiple vac-
cines produced no adverse reactions, as determined by
these assays.
Robust antibody response to individual antigens
We next examined antibody responses to assess biological
compatibility of the vaccines after i.d. administration.
Sera were collected after each vaccination and antigen-
specific antibodies were measured. All vaccines induced a
significant increase in specific IgG compared to control by
14 days after the primary vaccine administration (Table
1). Further enhancement of the immune response to each
vaccine was observed with each subsequent vaccination
(Fig. 2). The final recorded antibody levels for BoNT/
A(Hc), rPA and STEBVax were similar to previous values
for animals receiving individual i.m. vaccinations
[11,13,17,19] and F1-V responses were the highest. Serum
levels of BoNT/A-specific antibody were lowest compared
to all other antibodies except controls, likely as a result of
the small amount of BoNT/A(Hc) used for vaccinations.
Levels of antigen-specific IgM against all antigens were sig-
nificantly elevated compared to controls 2 weeks after the
final vaccine administrations (Table 1). We concluded
that levels of serum antibodies against each vaccine were
not altered by concurrent i.d. injection to sites that were in
close proximity to each other.
Neutralizing antibody responses
Standard assays were previously established for determin-
ing the level of antibodies present in sera that protect the
vaccinated host from SEB-toxic shock, botulism, and
anthrax. These neutralizing antibody assays provided an
additional parameter for predicting the outcome of expo-
sure to each agent of disease. The BoNT/A neutralizing
antibody titers were determined as the reciprocal of the
serum dilution that protected 50% of the mice from chal-
lenge with 10 LD50 of toxin. Serum from vaccinated pri-
mates protected CD-1 mice challenged with BoNT/A (Fig.
3A); serum from control animals was not protective. Anti-
bodies that neutralized B. anthracis were present in all vac-
cinated animals, but not in controls, as determined by
measuring inhibition of J774 cell lysis after exposure to
anthrax lethal toxin (Fig. 3B). Additionally, serum from
vaccinated animals prevented SEB-induced proliferation
of human peripheral blood mononuclear cells after addi-
tion of the toxin to culture (Fig. 3C). We could not deter-
mine the titers of neutralizing antibody against plague
because there were no previously validated assays availa-
ble for the rhesus monkey that permitted correlation of
antibody titer with protection from disease.
Protection from multiple bacterial and toxin-mediated 
diseases
The results up to this point demonstrated robust antibody
responses to all vaccines and these titers were similar or
identical to previous studies using monovalent i.m. vacci-Journal of Immune Based Therapies and Vaccines 2008, 6:5 http://www.jibtherapies.com/content/6/1/5
Page 6 of 11
(page number not for citation purposes)
Intradermal administration of the vaccines for anthrax (rPA), botulism [BoNT/A(Hc)], plague (rF1-V), and SEB induced toxic- shock (STEBVax) Figure 1
Intradermal administration of the vaccines for anthrax (rPA), botulism [BoNT/A(Hc)], plague (rF1-V), and 
SEB induced toxic-shock (STEBVax). A. Rhesus macaque skin immediately after vaccination (two sites, left to right): 
BoNT/A, rF1-V, rPA, and STEBVax. B. Rhesus macaque skin two months after vaccine administration. Marks are adjacent to 
injection sites. C. Skin sections (H&E stain) obtained from the vaccine delivery site exhibited epithelioid macrophages and 
multinucleated giant cells containing adjuvant (inset, green). Phalloidin staining of actin, red; Hoechst staining of DNA, blue. D. 
Macrophages at the vaccine delivery site exhibited high expression of MHC-II molecules (brown). Anti-MHC Class II immuno-
histochemistry (brown). E. Epithelioid macrophages (H&E stain) containing adjuvant (inset) were also present in the axillary 
lymph nodes of vaccinated animals. F. Vaccination did not significantly alter white blood cell counts of vaccinated animals (solid 
line) compared to control (dashed line). Mean cell counts ± SD of all animals studied.
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nations [11,13,17,19]. Therefore, we next evaluated pro-
tection of vaccinated animals from disease. The rhesus
macaques were healthy with no overt signs of disease or
pathology before challenge. The total white blood cell
counts and distribution of granulocytes, monocytes, and
lymphocytes remained within normal range throughout
the study for all vaccinated and control animals prior to
disease challenge, indicating minimal systemic inflamma-
tory responses to the multiple vaccines or method of
administration (Fig. 4A–C). These data were in accord-
ance with the general blood chemistry profiles (described
above). This cellular data was collected to follow any
potential toxicity resulting from the experimental method
and to address the outcome of vaccinations on the inflam-
matory response occurring during the early stage of dis-
ease onset. The animals were divided into four separate
challenge groups consisting of two controls and six vacci-
nated rhesus macaques. Each group was challenged by
aerosol with either BoNT/A, SEB, or B. anthracis (Ames)
spores and monitored for up to 2 months post-challenge.
All disease challenges occurred one month after the final
vaccination. Slight to moderate fluctuations in the distri-
bution of white cell populations were noted for all ani-
mals within the first 48 h following challenge with toxin
or bacteria (Fig. 4), perhaps due to a generalized inflam-
matory response to aerosol challenge. Efficacy was evalu-
ated by comparing the treated group to the control group
for each agent consisting of the 2 experimental controls
and 15 historical controls. Uniform lethality has been
observed in more than 15 untreated control rhesus
exposed to the same strain and route of each agent used in
the experiment (unpublished observations). Results indi-
cated that the percentage of animals surviving in each
treatment group (6/6 or 100%) was significantly higher
than the percentage of animals surviving in each pooled
control group (0/17 or 0%), p < 0.0001. Further details
concerning each disease challenge are described below.
All vaccinated animals receiving BoNT/A (65 × LD50 aver-
age) survived (Table 2) and exhibited no outward clinical
Table 1: Robust serum antibody response to simultaneous intradermal vaccination
Antibody concentration (μg/ml) mean ± SD
Vaccine
Isotype Day Treatment BoNT/A(H c) rF1-V rPA STEBVax
IgM 70 Control (n = 8) 3.07+/-0.87 2.99+/-1.47 6.31+/-3.16 4.76+/-3.62
70 Vaccinated (n = 24) 5.47+/-2.20 11.2+/-4.04 13.7+/-9.28 9.07+/-2.74
p-value* 0.0001 < 0.0001 0.002 0.012
IgG 14 Control (n = 8) 0.31+/-0.15 2.1+/-3.1 0.31+/-0.12 1.25+/-1.76
14 Vaccinated (n = 24) 1.4+/-1.1 421+/-196 86+/-46 121+/-109
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001
42 Control (n = 8) 0.28+/-0.22 1.95+/-0.98 2.2+/-1.4 1.23+/-0.91
42 Vaccinated (n = 24) 4+/-2.1 767+/-382 689+/-397 323+/-187
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001
70 Control (n = 8) 0.65+/-0.37 1.05+/-1.08 0.91+/-0.44 1.93+/-1.25
70 Vaccinated (n = 24) 48+/-13 2331+/-303 2245+/-1224 1340+/-215
p-value < 0.0001 < 0.0001 < 0.0001 < 0.0001
*Significance of mean serum IgM and IgG concentrations for control and vaccinated animals were compared using Student's t-test.
Concurrent intradermal administration of four independent  vaccines resulted in rapid seroconversion of specific IgG Figure 2
Concurrent intradermal administration of four inde-
pendent vaccines resulted in rapid seroconversion of 
specific IgG. Mean ± SD (triplicate determinations) of anti-
gen-specific IgG for all vaccinated animals. n BoNT/A(Hc) 
vaccine, h rF1-V vaccine, n STEBVax, s rPA vaccine. The 
arrows indicate the days of vaccine administration.
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signs of botulism. Both control animals survived for only
2 days after challenge and necropsy findings were sugges-
tive of death due to BoNT/A intoxication, although no
specific post-mortem lesions are induced by BoNT/A.
These findings included aspiration of foodstuff into the
trachea and lungs due to dysphagia secondary to cranial
nerve paralysis after exposure to the toxin. White blood
cell counts of the vaccinated animals were only slightly
affected by challenge. However, the average percentage of
lymphocytes and monocytes increased, while granulo-
cytes decreased until about 4 days post-challenge (Fig.
4A). Each cell population returned to normal pre-chal-
lenge levels by day 55 post-challenge.
All of the vaccinated animals survived challenge with SEB
(23 × LD50 average), showing no clinical signs of toxic
shock after challenge (Table 2). In contrast, control ani-
mals survived for only 2 days after challenge. Necropsy
and histopathology verified that death of the controls was
consistent with toxic shock caused by SEB. Total white
blood cells of the vaccinated animals did not significantly
change after challenge. Similar to profiles of vaccinated
animals surviving botulism, the percentage of lym-
phocytes and monocytes increased while the percentage
of granulocytes decreased until about day 4 (Fig. 4B). The
percentage of each cell type then returned to prechallenge
levels by day 55 postchallenge.
Control animals exposed to B. anthracis spores (377 ×
LD50) survived 4 days after challenge and death corre-
sponded with an increase in bacteremia detectable by day
4. The control animals exhibited increased blood mono-
cytes (2 d) and granulocytes (4 d), while lymphocytes
decreased by 4 days after challenge. Necropsy and his-
topathology verified that death was consistent with
anthrax. All spore-challenged animals that were vacci-
nated survived with no disease symptoms (Table 2), and
no significant changes in granulocytes, lymphocytes, or
monocytes were observed (Fig. 4C).
Discussion
Our data demonstrates that i.d. vaccination of multiple
antigens by a method that physically separates each com-
ponent circumvents the primary physical, chemical, and
biological incompatibilities that are common to combi-
nation vaccines prepared by mixing before administra-
tion. Our results with four unique diseases suggested that
we did not reach a biological limit to the number of vac-
cines that can be administered at one time and that there
was no apparent "vaccine overload" [1]. Any injection site
trauma appeared to be minor due to the minute size of the
needles used, consistent with a previous clinical study [3].
We observed small blebs on the skin of rhesus macaques
immediately after vaccination, resulting from the fluid
injected, while these sites were barely perceptible by the
end of the study and surrounding tissues returned to nor-
mal by 3 months. All of the vaccines we examined
induced significant levels of serum antibodies (IgM, IgG),
equivalent to historic data and neutralizing antibody titers
were observed for anthrax, BoNT/A, and toxic shock vac-
cines. All vaccinated rhesus macaques were protected
from an otherwise lethal anthrax, botulism and staphylo-
Potent neutralizing antibody responses of rhesus macaques receiving concurrent intradermal administrations of four independ- ent vaccines Figure 3
Potent neutralizing antibody responses of rhesus macaques receiving concurrent intradermal administrations 
of four independent vaccines. A. Neutralizing antibody titers for animals in: A. botulinum neurotoxin type A challenge 
group. B. anthrax challenge group. C. SEB challenge group. Individual animals vaccinated with antigens plus AH, Vaccinated 1–6; 
injected with AH only, Control 1–2. All disease challenges occurred one month after the final vaccination. Geometric mean tit-
ers, based on triplicate determinations.
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coccal toxic shock. Our results indicated that the percent-
age of animals surviving in each treatment group (6/6 or
100%) was significantly higher than the percentage of ani-
mals surviving in each pooled control group (0/17 or
0%), p < 0.0001. Collectively, these results indicate that
the vaccines were biocompatible by i.d. administration
and physical separation. Seroconversion also occurred
after the primary dose for each vaccine, though it is not
clear if this was dependent on the method of delivery. The
rF1-V vaccine was previously shown to be protective
against plague in mice [18,19] and this was confirmed
with the vaccine used in our study (data not shown). Yet,
there is a paucity of published data for efficacy of vaccines
based on the LcrV and CaF1 antigens in non-human pri-
mates. Antibody levels specific for rF1-V were the highest
among all of the vaccinated animals, suggesting that the
potency of this vaccine was maintained. Cellular immu-
nity, not addressed in our study, may also be important
for protection from plague [22]. We observed that the
minor perturbations of blood cell counts occurring within
days of challenge returned to normal for all vaccinated
animals.
Vaccination resulted in rapid recovery of white blood cell populations following disease challenge Figure 4
Vaccination resulted in rapid recovery of white blood cell populations following disease challenge. All disease 
challenges occurred one month after the final vaccination. Peripheral arterial blood was drawn at various time points postchal-
lenge and analyzed for changes in cellular composition. A. Botulinum neurotoxin type A; B. Staphylococcal enterotoxin B. C. B. 
anthracis (Ames) spores.
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Notably, the significance of our results should be consid-
ered in light of the general benefits of vaccination to soci-
ety. For example, there are substantial cost savings to the
individual and to the public resulting from protection
against the 11 diseases preventable by the current routine
childhood vaccination schedule [23]. However, there are
currently 28 recommended vaccines for children and
adults, plus annual influenza vaccinations. Additional
vaccines are planned for protection from the nine category
A and numerous B-C agents on the Centers for Disease
Control and Prevention (CDC) select agent list. Therefore,
developing a reasonable vaccination schedule that assures
patient compliance is a significant public health objective.
Combination vaccines offer one solution, yet these are
often difficult and costly to develop due to product
incompatibilities that may not be apparent during devel-
opment of individual component antigens.
Previous studies demonstrated that vaccine efficacy was
improved by targeting the dermis of the skin for delivery
[4,5,20,24-26], resulting in dose sparing by a mechanism
that is not clearly established. In our study, immune
responses to vaccines administered i.d. were not isolated
to the skin, though an enhancement of regional tissue
immunity may also have been possible. We observed that
the vaccines were internalized by dermal antigen-present-
ing cells and transported to the draining axillary lymph
nodes. It is unclear if physiological transport of the vac-
cines delivered i.d. differs substantially from i.m. vaccina-
tion. Regardless of the mechanism, it should also be
possible to increase the total number of vaccines that can
be administered to a small dermal site by lowering the
delivery volume for individual components because
reduced amounts of antigen are required for i.d. vaccina-
tion.
Conclusion
The physical separation of vaccines both in the syringe
and at the site of administration did not adversely affect
the biological activity of any component vaccine. Further,
the vaccination method we describe may be scalable to
include a greater number of antigens, while avoiding the
physical and chemical incompatibilities encountered by
combining multiple vaccines together in one product.
Our results demonstrate that intradermal delivery of mul-
tiple vaccine preparations may provide a practical alterna-
tive to traditional combination vaccines and complicated
administration schedules.
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